SwedenSweden

Nestlé catches BioGaia bacillus

08.03.2012

Swiss Nestlé S.A. has extended its collaboration agreement with BioGaia AB. The world’s largest nutrition company is paying up to €50.8m for a perpetual licence to use BioGaia’s patented Lacto­bacillus reuteri in infant nutrition products. BioGaia is receiving an upfront payment of a40m in the first quarter of 2012, and an additional a10.8m on achieving certain milestones in the next five years. Nestlé also has the option to extend the use of L. reuteri to other product areas. “Through the new agreement we have secured income that otherwise would not have been guaranteed under the original contract,” said Peter Rothschild, President of BioGaia. The Stockholm-based company announced it will use the proceeds to “further invest in its own brand” and for “a generous dividend policy”. A recent double-blind study in Indonesia showed that L. reuteri significantly reduced episodes of diarrhea. In the trial, 494 children received low lactose milk with or without L. reuteri or L. casei 431. The incidence of diarrhea episodes fell by 32% in the group supplemented with L. reuteri compared to placebo.
In the last few years, Nestlé has moved significantly into the field of functional food. In September 2010 it announced it would invest about US$500m in a new venture called Nestlé Health Science.

SwedenSweden

14.04.2011

Stockholm – Swedish Orphan Biovitrum AB (SOBI) has reported weak results for 2010. The company’s net income declined by 7.7% to SEK1.9bn, with losses for the period totalling up to SEK104m. SOBI spokesmen said that several...

SwedenSweden

06.04.2011

Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR...

SwedenSweden

08.02.2011

Stockholm – At the end of last year, the first European patient was treated with Ruconest – a recombinant C1 esterase inhibitor for the treatment of hereditary acute angioedema attacks developed by the Dutch Pharming Group NV and...

SwedenSweden

10.12.2010

Lund/Jerusalem – Active Biotech’s oral small molecule immunomodulator laquinimod (ABR-215062) has reached the primary endpoint of statistically significant reduction in annualized relapse rate compared to placebo, according to...

SwedenSweden

04.11.2010

Stockholm – Swedish Orphan Biovitrum AB (Sobi) and Dutch partner Pharming Group NV received market authorisation for Ruconest (rhucin) at the end of October. Intended for use in acute attacks of Hereditary Angioedema (HAE), the...

SwedenSweden

25.10.2010

Stockholm - Swedish researchers have unravelled the three-dimensional structure of the egg receptor, paving the way for new treatments of infertility and novel contraceptives. The team headed by Luca Jovine at Karolinska...

SwedenSweden

16.09.2010

Uppsala – Orexo AB has announced a bold new strategy. The company listed on the Stockholm stock exchange intends to develop and commercialise its own products from now on rather than out-licensing them to international partners....

SwedenSweden

15.09.2010

Linköping – In the first clinical study of its kind, Swedish researchers have proven that biosynthetic corneas can offer a real alternative to rare human replacement corneas. In a process developed by Per Fagerholm and May...

SwedenSweden

14.09.2010

Stockholm – A recent study from the Karolinska Institute reveals how two types of cellular changes interact in the development of cancer, and the results could improve the chances of early discovery of sarcomas. Pancreatic cancer...

Displaying results 21 to 30 out of 182

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-sweden/browse/2/article/nestle-catches-biogaia-bacillus.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4290.4%
  • CO.DON2.51 EUR191.9%
  • PAION2.43 EUR164.1%

FLOP

  • CYTOS0.25 CHF-93.9%
  • MEDIGENE4.53 EUR-69.2%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 01.09.2014


Current issue

All issues

Product of the week

Products